Yahoo Finance Here's Why Amedisys (AMED) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.
Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.
Why Investors Should Pay Attention to This Value Stock
Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.
Amedisys (AMED)
Amedisys Inc. provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, as well as various rehabilitative programs. It provides hospice services to patients through an interdisciplinary care team which includes nurse practitioners and other skilled nurses, social workers, aides, bereavement counselors and chaplains. Amedisys was founded in 1982 and is headquartered in Baton Rouge, LA.
AMED boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #2 (Buy) rating. Shares of Amedisys are trading at a forward earnings multiple of 21.3X, as well as a PEG Ratio of 2.4, a Price/Cash Flow ratio of 15.9X, and a Price/Sales ratio of 1.4X.
A company's earnings performance is important for value investors as well. For fiscal 2024, one analyst revised their earnings estimate higher in the last 60 days for AMED, while the Zacks Consensus Estimate has increased $0.00 to $4.57 per share. AMED also holds an average earnings surprise of 2.8%.
Investors should take the time to consider AMED for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amedisys, Inc. (AMED) : Free Stock Analysis Report
